SEC
NVCR icon

Seven Eight Capital’s NovoCure NVCR Stock Holding History

Seven Eight Capital’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,292
Closed -$911K – 425
2024
Q3 		$911K Sell
58,292
-3,617
-6% -$65.6K 0.08% 427
2024
Q2 		$1.06M Buy
+61,909
New +$1.09M 0.11% 339
2024
Q1 		– Sell
-109,432
Closed -$1.63M – 751
2023
Q4 		$1.63M Sell
109,432
-28,289
-21% -$379K 0.19% 154
2023
Q3 		$2.22M Buy
137,721
+71,989
+110% +$2.08M 0.26% 100
2023
Q2 		$2.73M Buy
+65,732
New +$4.08M 0.45% 60
2018
Q4 		– Sell
-48,301
Closed -$2.53M – 661
2018
Q3 		$2.53M Buy
+48,301
New +$1.92M 0.15% 204
2018
Q1 		– Sell
-33,600
Closed -$679K – 490
2017
Q4 		$679K Buy
+33,600
New +$647K 0.07% 299

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Seven Eight Capital's NVCR Position: Q4 2024 in Review

Seven Eight Capital sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 58,292 shares — an estimated $911K sold.

Seven Eight Capital first reported a position in NVCR in Q4 2017 and held it in 7 quarters. The position peaked at $2.73M in Q2 2023. 239 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Seven Eight Capital reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 58,292 NovoCure shares in Q4 2024, an estimated $911K.
  • Seven Eight Capital first reported a position in NovoCure in Q4 2017 and held it in 7 quarters.
  • Seven Eight Capital's NovoCure position peaked at $2.73M in Q2 2023.
  • 239 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.